GOVERNANCE
Board of Directors
The Board holds the broadest powers of administration and management over the Association and it is subjected to the powers reserved to the General Assembly.
Scientific Steering Committee
The Steering Committee defines and steer the scientific and medical strategy of ACCELERATE. It is a multi-stakeholder group, and each stakeholder has an equal voice.
Academia
Gilles Vassal
(Chair)
Institut Gustave Roussy, France
Lynley Marshall
Royal Marsden Hospital, UK
Steven DuBois
Dana-Farber / Boston Children’s Cancer and Blood Disorders Center, USA
Lia Gore
Children’s Hospital Colorado, USA
Patients Advocates
Donna Ludwinski
Solving Kids' Cancer, USA
Patricia Blanc
Imagine For Margo, France
Nicole Scobie
Patient Advocate, Switzerland
Antonia Palmer
Kindred Foundation, Canada
Regulators
Martha Donoghue
Food and Drug Administration (FDA), USA
Dominik Karres
European Medicines Agency (EMA), The Netherlands
Sara Galluzzo
Member Scientific Advice Working Party (SAWP) at EMA, Italian
Brenda Weigel
Chair of FDA Pediatric Oncologic Drugs Advisory Committee (ODAC), USA
Industry
Elly Barry
Day One Pharmaceuticals, USA
Hubert Caron
Roche, Swizerland
Peter Adamson
Sanofi, USA
Anjali Sharma
Gilead Sciences, USA
Intuitu Personae
Olga Kholmanskikh
Federal Agency for Medicines and Health Products, Belgium
General Assembly
The General Assembly holds the broadest powers enabling ACCELERATE to achieve its purpose, including those to appoint/remove members of the Board as well as to approve budgets and accounts.
Team
The ACCELERATE team has an office in Brussels led by the Director of Operations, which reports to the Board of Directors.
Volunteers
ACCELERATE gathers a network of more than a thousand of volunteers and participants who bring an immense added value to our work. We would like to thank them all for their hard work and for being part of the ACCELERATE initiative!
Supported by
